Left ventricular dysfunction: which role for calcium antagonists?
|
|
- Stella Harris
- 6 years ago
- Views:
Transcription
1 European Heart Journal (1997) 18 {Supplement A), A87-A91 Left ventricular dysfunction: which role for calcium antagonists? S. Iliceto Cattedra di Cardiologia, Universita' di Cagliari, Italy Left ventricular dysfunction is the most common cause of congestive heart failure. Thus, treating or preventing left ventricular dysfunction represents an important therapeutic goal. The use of calcium antagonists in the treatment of left ventricular dysfunction or congestive heart failure has been proposed for many years now, mainly because of their potent vasodilatory effect. However, despite the theoretical basis, the results of studies exploring the possible use of calcium antagonists in this setting have not been at all encouraging. It has been suggested that this is because calcium antagonists have important additional effects: they depress cardiac contractility and activate the neurohormonal system. The various calcium antagonists have different characteristics and can be potentially useful in a variety of clinical conditions. Amlodipine (a calcium antagonist with a minimal cardiodepressant effect, long half-life and minimal activity on the neurohormonal system) has been shown to be clinically useful in congestive heart failure of nonischaemic origin. Calcium antagonists capable of limiting heart rate increment are useful in limiting ischaemia-induced left ventricular dysfunction. Verapamil exerts a potent protective effect on both microvascular damage and mechanical recovery during prolonged ischaemia followed by reperfusion. Lastly, nisoldipine is capable of ameliorating left ventricular function in patients with left ventricular diastolic dysfunction and has, therefore, potential in the treatment of congestive heart failure of left ventricular diastolic dysfunction origin. Thus, calcium antagonists may have a role in the treatment of left ventricular dysfunction provided that patient characteristics, the underlying mechanisms of the left ventricular dysfunction and the various calcium antagonist characteristics are well understood and carefully considered. (Eur Heart J 1997; 18 (Suppl A): A87-A91) Key Words: Calcium antagonist, congestive heart failure, left ventricular dysfunction. Introduction Left ventricular dysfunction is the result of many cardiac disorders causing a mechanical alteration of cardiac performance. More importantly it can be the main cause of congestive heart failure. Given the clinical and prognostic impact of congestive heart failure, it is clear why much attention is paid to both the prevention and treatment of left ventricular dysfunction. Left ventricular dysfunction can involve the entire left ventricle (overall left ventricular dysfunction) or only part of it (regional left ventricular dysfunction). The latter is particularly common in coronary artery disease, because of the regional nature of the disease and can, moreover, evolve into more severe overall left ventricular dysfunction and dilatation (left ventricular remodelling phenomenon). Correspondence: Prof. Sabino Iliceto, Institute of Cardiology, University of Cagliari, Via San Giorgio, 12, Cagliari, Italy X/97/0A $18.00/0 Lastly, left ventricular dysfunction can be either systolic or diastolic, the latter being less uncommon than previously thought. The role of calcium antagonists in the treatment of left ventricular dysfunction Data so far on the use of calcium antagonists in left ventricular dysfunction, and more importantly in the treatment of congestive heart failure, its main consequence, have been somewhat conflicting. The question has recently become even more important, as it has been suggested on the basis of some metaanalyses that this category of drugs might even be dangerous' 11. Therefore, it seems worthwhile to review some important concepts and data that could be helpful in understanding the advantages, disadvantages, 1997 The European Society of Cardiology
2 A88 S. Iliceto et al limitations and specific indications of calcium antagonists in the treatment of left ventricular dysfunction with or without congestive heart failure. Theoretical bases for the use of calcium antagonists for the treatment of congestive heart failure An important effect of all calcium antagonists is their (more or less pronounced) vasodilatory effect. This is of great benefit in patients with congestive heart failure, in whom systemic vasoconstriction exerts a negative effect on cardiac performance. It has been thought that the beneficial effect of calcium antagonists might be even greater in patients with coronary artery disease, since they can have various forms of myocardial ischaemia that can cause worsening of regional left ventricular function. Calcium antagonists chiefly limit the extent and severity of myocardial ischaemia via reduced oxygen demand and augmented coronary blood flow. These relevant effects (reduction of systemic vascular resistance, limited extent of regional left ventricular dysfunction in the course of acute myocardial ischaemia, increased coronary blood flow) have favoured their use in the treatment of congestive heart failure, especially if it is of ischaemic origin. This is probably why, in the SOLVD Trial, calcium antagonists were found to be used in approximately 30% of cases with congestive heart failure. The use of calcium antagonists in the treatment of congestive heart failure is further supported by studies demonstrating that they can exert a consistent beneficial effect on left ventricular function in experimental models of heart failure. This is the case, for example, in Syrian hamster cardiomyopathy induced by calcium overload and micro vascular spasm. Unfortunately, these theoretical considerations have not found the expected confirmation in experimental and clinical studies. Despite the expected vasodilatory effect no clinical benefit has been observed in a series of patients, whether in limited or in large trials. Verapamil administration in patients with coronary artery disease and depressed left ventricular function further improves contractility when left ventricular ejection fraction is less than 30%' 2). Long-term therapy with diltiazem increases cardiovascular mortality and morbidity in patients with acute myocardial infarction and clinical signs of congestive heart failure' 31. Longterm administration of nifedipine, either alone or in combination with isosorbide dinitrate, in patients with mild to moderate chronic heart failure significantly worsened heart failure' 41. The reason for the great discrepancy between theoretical considerations and clinical observations needs elucidation. Why do calcium antagonists not exert a clinical benefit in patients with congestive heart failure? The absent or, sometimes even deleterious effects of calcium antagonists in patients with congestive heart failure have been attributed to one or both of the following mechanisms: negative effect on myocardial contractility; neurohormonal activation. myocardial contractility Calcium antagonists' negative effects on calcium transmembrane transport reduce myocardial contractility. This cardiodepressant effect has been thought to be the potential source of the observed negative clinical results. However, it has also been noticed that this depressant effect can be counterbalanced by peripheral vasodilatation and especially by reflex sympathetic activation. This counterbalancing mechanical effect is, unfortunately, of little value in patients with congestive heart failure for two reasons. Firstly, intracellular delivery of calcium to the contractile apparatus is greatly impaired in patients with congestive heart failure' 5 ' 61 ; thus, in these patients calcium antagonists may even further depress left ventricular contractility. Secondly, in patients with congestive heart failure, the capacity to respond to inotropic stimulus induced by sympathetic reflex activation is severely blunted. On these grounds the use of calcium antagonists should be avoided in patients with advanced forms of congestive heart failure, especially in conjunction with beta-blockers. The cardiodepressant effect seems unlikely to be the explanation for these negative clinical results, since other drugs exerting a negative inotropic effect (such as beta-blockers) have shown a positive effect in the same clinical environment. Calcium antagonists and neurohormonal activation The neurohormonal system is activated by calcium antagonists in two different ways. In the first place, peripheral vasodilation (however it is caused) is a well known stimulus for renin release; secondly, calcium exerts an inhibitory effect on renin release' 7 ' 81. Hence calcium antagonists theoretically neutralize this inhibitory mechanism. Activation of the renin-angiotensin system induces deleterious effects in patients with congestive heart failure. Vasoconstriction, salt and water retention occur when this system is activated; moreover, the renin-angiotensin system can bring about the development of complex ventricular arrhythmias. This is the result of potassium depletion that can occur because of the increased production of mineralocorticoids. All these
3 Calcium antagonists in left ventricular dysfunction A89 effects have, obviously, a very negative functional impact on patients with congestive heart failure. However, it is important to note that other treatments for congestive heart failure which can activate the reninangiotensin system via vasodilation (hydralazine, isosorbide dinitrate) have a positive clinical effect in patients with congestive heart failure' 91. This different effect suggests that drugs activating the neurohormonal system exert negative clinical effects in patients with congestive heart failure only when they are also capable of depressing myocardial contractility. Calcium antagonists in congestive heart failure: new approaches Calcium antagonists could be used for the treatment of congestive heart failure provided that particular conditions are met: (a) minimal inotropic effect on myocardium, or, better still no negative inotropic effects at all (b) a combination of calcium antagonists with ACE inhibitors to counterbalance the negative effects caused by neurohormonal activation, (c) the development of new calcium antagonists that do not activate the neurohormonal system. Recent studies suggest that amlodipine, a second-generation dihydropyridine calcium antagonist, has functional and clinical benefits for patients with congestive heart failure. In a first multicentre, doubleblind, placebo-controlled study it was shown that in patients with congestive heart failure treated with diuretics, ACE inhibitors and amlodipine, exercise time significantly improved, both at 4 and 8 weeks, in comparison to patients treated with placebo. Moreover, symptoms were also significantly improved in patients receiving amlodipine. Interestingly, these favourable functional and clinical findings were also associated with a significant reduction in plasma levels of norepinephrine [10). These promising data, collected in a series of 118 patients, have found a more solid confirmation in the PRAISE trial. This involved 1153 patients with congestive heart failure in NYHA class II-IV'" 1. Preliminary results show that in patients with congestive heart failure of non-ischaemic origin, amlodipine not only improved survival but also reduced the combined risk of mortality and morbidity in a 14-month follow up. In a study of felodipine in patients with congestive heart failure (Class II, III NYHA), the effects of the drug were ambiguous. regional systolic dysfunction As previously mentioned, overall left ventricular dysfunction can be the result of adaptive evolution of a serious regional dysfunction. This condition is called 'left ventricular remodelling phenomena'. It mainly occurs in ischaemic heart disease since this can affect the left ventricle in a regional manner. Thus, it seems logical to attempt, when possible, a therapeutic approach aimed at limiting, if not even eliminating, the regional dysfunction, which is the main mechanism of progressive left ventricular enlargement. Calcium antagonists can play a very important role here, both in reducing the extent of dysfunctioning myocardium caused by myocardial ischaemia and in improving the functional recovery of post-ischaemic dysfunctional, but viable, myocardium. Calcium antagonists, by reducing oxygen demand and improving coronary blood supply during ischaemia, exert a beneficial functional effect on left ventricular function in the course of acute myocardial ischaemia. In a study in which diltiazem was administered in patients with acute myocardial infarction undergoing exercise radionuclide angiography it was shown that both ejection fraction and regional wall motion score improved after calcium antagonist administration' 121. Verapamil administration in an ischaemiareperfusion experimental model considerably improved both the degree and time course of recovery of postischaemic dysfunctioning myocardium' 131. This beneficial effect was particularly evident when verapamil was administered before development of ischaemia or even at the time of reperfusion. This functional improvement may be due to a direct protective effect of verapamil on myocytes during both ischaemia and reperfusion and/or, as recently suggested, to protection of microvasculature and consequent reduction of the 'no reflow' phenomenon' 141. Experimental studies have shown that during ischaemia followed by reperfusion, microcirculatory damage occurs well before myocyte death develops' 151. In patients with recent myocardial infarction, preservation of microvasculature integrity and function guarantees viability as assessed by either functional recovery at follow-up or by contractile reserve at dobutamine stress echo-cardiography' 16 " 181. On the other hand, patients without adequate reperfusion, despite infarct-related artery re-opening after acute myocardial infarction ('no reflow phenomenon'), have a poor functional outcome after the acute event. Gallopamil and verapamil are capable of reducing the percentage extent of the no reflow phenomenon within the risk area after prolonged myocardial ischaemia. It has been suggested that this beneficial effect can be attributed to different mechanisms, including a possible antispastic effect on microvasculature'' 4 ' 191. This possible mechanism has been recently suggested by Piana and colleagues in a clinical study in which verapamil was successfully used to limit or abolish the no reflow phenomenon occurring after percutaneous transluminal coronary angioplasty' 20 '. diastolic left ventricular dysfunction Congestive heart failure can be caused not only by systolic regional or global left ventricular dysfunction, but also by diastolic dysfunction. This last possibility is
4 A 90 S. Iliceto et al much less uncommon than previously thought. A recent survey of 31 scientific papers regarding congestive heart failure has demonstrated that a normal systolic function can be observed in approximately 35-40% of patients with congestive heart failure and that this percentage tends to increase with age' 2 ' 1. The same review has shown that prognosis for patients with congestive heart failure of diastolic origin is better than for those with systolic dysfunction. The importance of diastolic dysfunction in severe congestive heart failure has been emphasised by the Mayo Clinic group. In a series of patients with congestive cardiomyopathy followed up for some years, these investigators have shown that if diastolic dysfunction is present along with systolic impairment, survival is decidedly lower' 221. Nisoldipine is a calcium antagonist whose positive effect on left ventricular diastolic performance has been demonstrated in a clinical setting. In the light of this promising potential, the DEFIANT Trial was performed In this trial, carefully selected patients with recent acute myocardial infarction were randomly assigned to nisoldipine or placebo. Left ventricular diastolic performance was evaluated by Doppler echocardiography before and after treatment. The DEFIANT results have shown that treatment with nisoldipine improves Doppler indexes of left ventricular diastolic performance. These results formed the basis for the DEFIANT II trial aimed at evaluating the effect of nisoldipine on exercise time in patients with myocardial infarction. Despite the premises, no clinical benefit was found. This is probably because not all patients with myocardial infarction had left ventricular dysfunction of diastolic origin, thus treating all patients (regardless of left ventricular diastolic status) can make it difficult to unmask the benefit occurring in a selected minority of patients. Verapamil has also been shown to have a beneficial therapeutic effect in patients with congestive heart failure, preserved systolic left ventricular function and improved diastolic filling. In a series of patients with such characteristics, Setaro et al. [24] observed a significant improvement in exercise capacity in those patients treated with verapamil. Conclusions Calcium antagonists may have a role in the treatment of left ventricular dysfunction. The different characteristics of various calcium antagonists, as well as differences in pathophysiology of various forms of left ventricular dysfunction and congestive heart failure must be well understood and considered when treating the single patient. Not all calcium antagonists can be given to all patients with left ventricular dysfunction or congestive heart failure. There are, however, specific clinical conditions in which calcium antagonists can be indicated and utilised. In established congestive heart failure a calcium antagonist with minimal cardiodepressant effect, long half life and exerting a minimal activation of neurohormonal system can be used. PRAISE trial results suggest that amlodipine meets these criteria and can be used in patients with congestive heart failure of non-ischaemic origin. However, calcium antagonists may also have a role in the early stage of congestive heart failure, when left ventricular diastolic dysfunction can be limited. Calcium antagonists limiting heart rate increments may have a role in left ventricular dysfunction of ischaemic origin. Verapamil has been shown to be effective in limiting the no reflow phenomenon after acute ischaemia and in ameliorating mechanical recovery. Thus, calcium antagonists may have a potential role in the very acute phase of myocardial infarction for a limited period of time in patients in whom infarcted-related artery reopening has been successfully achieved by thrombolysis or percutaneous transluminal coronary angioplasty (PTCA). This hypothesis is currently being tested in a multicentre trial (VAMI: Verapamil in Acute Myocardial Infarction). In this trial, patients with acute anterior myocardial infarction treated with thrombolysis within 4 h of chest pain onset are monitored over time by digital echocardiography. Digital echocardiograms are transmitted telephonically to a core laboratory for central reading' 251. Lastly, in some patients in whom left ventricular dysfunction of diastolic origin is present, nisoldipine could be potentially useful in ameliorating left ventricular dysfunction and in preventing further left ventricular deterioration. Thus, accurate knowledge of patient history, the underlying mechanism of left ventricular dysfunction and pathophysiology are essential for optimum calcium antagonist administration in patients with left ventricular dysfunction. References [1] Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: [2] Klein HO, Ninio R, Oren V, Lang R et al. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment of equilibrium-gated radio nuclide ventriculography. Circulation 1983; 67: [3] Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S, the Adverse Experience Committee, the Multicenter Diltiazem. Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: [4] Elkayamu, Amin J, Mehra A et al. A perspective, randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: [5] Harigaya S, Schwartz A. Rate of calcium binding and uptake in normal animal and failing human cardiac muscle: Membrane vesicles (relaxing system) and mitochondria. Circ Res 1969; 25: [6] Limas CJ, Olivari MT, Goldenberg IF, Levine TB, Benditt DG, Simon A. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987; 21: Eur Heart J. Vol. 18. Suppl A 1997
5 Calcium antagonists in left ventricular dysfunction A91 [7] Fray JCS, Lush DJ, Valentine AMD. Cellular mechanisms of renin secretion. Fed Proc 1983; 42: [8] Churchill PC. Possible mechanism of the inhibitory effect of ouabain on renin secretion from rat cortical slices. J Physiol 1979; 294: [9] Cohn JN, Archibald DG, Ziesche S, Franciosa JA et al. Effect of vasodilation therapy on mortality in congestive heart failure. Results of a veteran administration cooperative study. N Engl J Med 1986; 314: [10] Packer M, Nicod P, Khanderia BR et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild to moderate heart failure. (Abstr) J Am Coll Cardiol 1991; 17: 274A. [11] Pressler ML, Carson PE, Miller AB et al. PRAISE Investigators, Indiana University. Safety of amlodipine in severe heart failure: Reduction of sudden death in non-ischemic heart disease. (Abstr) J Am Coll Cardiol 1996; 27 (2, Suppl A): 281A. [12] van der Wall EE, Niemieyer MG, Vliegen HW et al. Improvement of left ventricular function in silent ischemia following myocardial infarction, after administration of diltiazem. J Cardiovascular Pharmacology 1991; 18 (Suppl 9): S68-S72. [13] Przyklenk K, KJoner RA. Effect of verapamil on post ischemic 'stunned' myocardium: importance of the timing of treatment. J Am Coll Cardiol 1988; 11: [14] Taniyama Y, Ito H, Iwakura K, Takiuchi S, Maruyama A, Fuji K. Effects of intracoronary injection of Verapamil and Nicorandil on microcirculation and left ventricular function in patients with reperfused myocardial infarction. Circulation Abs 1995; 92 (Suppl I): [15] Kloner RA, Ganote CE, Jennings RB. The 'no flow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: [16] Ito H, Tomooka T, Sakai N et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: [17] Sabia PJ, Powers ER, Ragosta M et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327: [18] Iliceto S, Galiuto L, Marchese A et al. Analysis of microvascular integrity, contractile reserve and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J Cardiol 1996; 77: [19] Villari B, Ambrosio G, Golino P et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-refiow phenomenon in reperfused hearts. Am Heart J 1993; 125: [20] Piana RA, Paik GY, Moscucci M et al. Incidence and treatment of'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: [21] Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiological perspective. J Am Coll Cardiol 1995; 26: [22] Rihal CS, Nishimura RA, Hatle LK el al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 1994; 90: [23] The DEFIANT (Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy) Research Group. Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT Study. Eur Heart J 1992; 13: [24] Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: [25] Iliceto S, D'Ambrosio G, Scrutinio D, Marangelli V, Boni L, Rizzon P. A digital network for long-distance echocardiographic image and data transmission in clinical trials: the CEDIM Study experience. J Am Soc Echocardiogr 1993; 6:
Heart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationNo-reflow Phenomenon in Patients with Acute Myocardial Infarction: Its Pathophysiology and Clinical Implications
No-reflow Phenomenon in Patients with Acute Myocardial Infarction: Its Pathophysiology and Clinical Implications * 164 Ito Acta Med. Okayama Vol. 63, No. 4 Normal case Anterior MI Fig. 3 Myocardial contrast
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationfunction in patients with ischaemic heart disease
Br. J. clin. Pharmac. (1986), 22, 319S-324S Calcium antagonist treatment and its effects on left ventricular function in patients with ischaemic heart disease E. A. RODRIGUES, I. M. AL-KHAWAJA, A. LAHIRI
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationDOWNLOAD PDF ABC OF HEART FAILURE
Chapter 1 : The ABCs of managing systolic heart failure: Past, present, and future Heart failure is a multisystem disorder which is characterised by abnormalities of cardiac, skeletal muscle, and renal
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationCORONARY ARTERY DISEASES
CORONARY ARTERY DISEASES It has been estimated that over one third of the population eventually will die of CAD, and 20% will develop symptoms when younger than age 60 years. ANATOMY OF THE CORONARY ARTERIES
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPROVIDING antegrade coronary flow during AMI limits myocardial necrosis 1)
Clinical Studies Treatment of No-Reflow Phenomenon with Verapamil after Primary Stent Deployment during Myocardial Infarction Ibrahim DEMIR, 1 MD, Huseyin YILMAZ, 1 MD, Cengiz ERMIS, 1 MD, and Oktay SANCAKTAR,
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationMedical Policy and and and and
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationΧ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν
Χ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν Efficacy of Myocardial Contrast Echocardiography in the Diagnosis and Risk Stratification of Acute Coronary Syndrome Am J Cardiol 2005;96:1498 1502
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationCardiovascular Imaging Stress Echo
Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationAngina and left ventricular dysfunction
European Heart Journal (1996) 17 {Supplement G), 2-7 Angina and left ventricular dysfunction H. J. Dargie From the CRI in Heart Failure, University of Glasgow, Glasgow, U. K. Angina with left ventricular
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationMaria Angela S. Cruz-Anacleto, MD
Maria Angela S. Cruz-Anacleto, MD 57/Female Menopausal Non-HTN, non-dm Hypothyroid (s/p RAI 1997) Levothyroxine 100 ug OD 5 Months PTA Chest discomfort Stress Echocardiography 5 Months PTA Chest discomfort
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationPharmacology. Drugs affecting the Cardiovascular system (Antianginal Drugs)
Lecture 7 (year3) Dr Noor Al-Hasani Pharmacology University of Baghdad College of dentistry Drugs affecting the Cardiovascular system (Antianginal Drugs) Atherosclerotic disease of the coronary arteries,
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationMajor differences among the three classes of calcium antagonists
European Heart Journal (1997) 18 {Supplement A), A56-A70 Major differences among the three classes of calcium antagonists R. Ferrari Chair of Cardiology, University of Brescia; Salvatore Maugeri Foundation,
More informationHeart failure update Treatment of heart failure with a normal left ventricular ejection fraction in the elderly
HEART FAILURE Heart failure update Treatment of heart failure with a normal left ventricular ejection fraction in the elderly Wilbert S. Aronow, MD Heart failure (HF) affects approximately 5 million persons
More informationMeasuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D.
Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D. Chronology of ISDN/Hydralazine ISDN/HYD V-HeFT I BIDIL Sub-group
More informationMechanisms and role of contrast echocardiography
Mechanisms and role of contrast echocardiography Seol Sang-Hoon Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea Physical Principles of Contrast Ultrasound Contrast echocardiography
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationIn acute myocardial infarction (AMI), early restoration of
Impact of Microvascular Dysfunction on Left Ventricular Remodeling and Long-Term Clinical Outcome After Primary Coronary Angioplasty for Acute Myocardial Infarction Leonardo Bolognese, MD, FESC; Nazario
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationA. W. J. van t Hof, A. Liem, H. Suryapranata, J. C. A. Hoorntje, M.-J de Boer and F. Zijlstra
European Heart Journal (1998) 19, 118 123 Clinical presentation and outcome of patients with early, intermediate and late reperfusion therapy by primary coronary angioplasty for acute myocardial infarction
More informationLeft ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy
Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationWHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.
WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationTypical chest pain with normal ECG
Typical chest pain with normal ECG F. Mut, C. Bentancourt, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Male 41 y.o. Overweight, hypertension, high cholesterol,
More informationDownloaded from ismj.bpums.ac.ir at 22: on Thursday March 7th 2019
- ( ) - ST. :. (No-reflow). ST :.. SPSS. ( / ) :.(P
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationStress echo workshop STRESSORS
Stress echo workshop STRESSORS Adham Ahmed, MD Lecturer of Cardiology, Ain Shams Indications of Stress Echo CAD Diagnosis Prognosticat ion 1 Physiologic Basis 1930s: Tennant and Wiggers Relationship between
More informationDRUGS USED IN ANGINA PECTORIS
DRUGS USED IN ANGINA PECTORIS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 16, 2010 Materials on: Exam #7 Required reading: Katzung, Chapter 12 1 TYPES OF ISCHEMIC HEART DISEASE
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationCHRONIC CAD DIAGNOSIS
CHRONIC CAD DIAGNOSIS Chest Pain Evaluation 1. Approach to diagnosis of CAD 2. Classification of chest pain 3. Pre-test likelihood CAD 4. Algorithm for chest pain evaluation in women 5. Indications for
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationof acute myocardial perfusion is associated with more complete and early functional recovery. (Heart 1999;81:12 16)
2 Heart 999;8:2 6 Acute assessment of microvascular perfusion patterns by myocardial contrast echocardiography during myocardial infarction: relation to timing and extent of functional recovery D Czitrom,
More informationHeart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationP F = R. Disorder of the Breast. Approach to the Patient with Chest Pain. Typical Characteristics of Angina Pectoris. Myocardial Ischemia
Disorder of the Breast Approach to the Patient with Chest Pain Anthony J. Minisi, MD Department of Internal Medicine, Division of Cardiology Virginia Commonwealth University School of Medicine William
More informationPhysiological rationale for co-treatment with
Br Heart J 1994;72 (Supplement):S 63-67 Cardiovascular Division, Department of Medicine, University of Minesota Medical School, Minneapo}is, Minnesota, USA Jay N Cohn Correspondence to: Dr Jay N Cohn,
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationManagement of Myocardial Infarction & Congestive Heart Failure. Dr. Dionne Dames-Rahming
Management of Myocardial Infarction & Congestive Heart Failure Dr. Dionne Dames-Rahming Myocardial Infarction Objectives of Medical Management Decrease morbidity Reduce further myocardial damage or injury
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationResults of Ischemic Heart Disease
Ischemic Heart Disease: Angina and Myocardial Infarction Ischemic heart disease; syndromes causing an imbalance between myocardial oxygen demand and supply (inadequate myocardial blood flow) related to
More information1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and
1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationMyocardial Wall Thickness Predicts Recovery of Contractile Function After Primary Coronary Intervention for Acute Myocardial Infarction
Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.035
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationGoing to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern
Going to high altitude with heart disease Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern stefano.rimoldi@insel.ch There are very few studies on patients with heart disease going
More informationΔυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;
Ελληνική Καρδιολογική Εταιρεία Σεμινάρια ομάδων εργασίας Θεσσαλονίκη, 8-10 Φεβρουαρίου 2018 Ομάδα εργασίας Ηχωκαρδιολογίας Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ; ΑΓΑΘΗ-ΡΟΖΑ
More informationMYOCARDIAL INFARCTION
338 JACC Vol. 31, No. 2 MYOCARDIAL INFARCTION Tissue-Type Plasminogen Activator Therapy Versus Primary Coronary Angioplasty: Impact on Myocardial Tissue Perfusion and Regional Function 1 Month After Uncomplicated
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationInvited Experts' Case Presentation and 5-Slides Focus Review
Invited Experts' Case Presentation and 5-Slides Focus Review FFR and IVUS in Myocardial Bridging Haegeun, Song. M.D. Heart Institute, Asan Medical Center, Seoul, Korea Myocardial Bridging Common congenital
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More informationAngina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room
Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationGated blood pool ventriculography: Is there still a role in myocardial viability?
Gated blood pool ventriculography: Is there still a role in myocardial viability? Oliver C. Alix, MD Adult Clinical and Nuclear Cardiology St. Luke s Medical Centre - Global City Case Presentation A 62-year-old
More informationDobutamine Kills Good Hearts! Levosimendan May Not
ISPUB.COM The Internet Journal of Cardiology Volume 2 Number 1 Dobutamine Kills Good Hearts! Levosimendan May Not S Kumar Citation S Kumar. Dobutamine Kills Good Hearts! Levosimendan May Not. The Internet
More informationCONGESTIVE HEART FAILURE IN PATIENTS WITH SYSTEMIC HYPERTENSION: A RETROSPECTIVE ANALYSIS WITH GATED BLOODPOOL SCINTIGRAPHY
CONGESTIVE HEART FAILURE IN PATIENTS WITH SYSTEMIC HYPERTENSION: A RETROSPECTIVE ANALYSIS WITH GATED BLOODPOOL SCINTIGRAPHY Abstract L. Beÿer & A.C. Otto Congestive heart failure (CHF) is a clinical syndrome
More informationInitial Medical and Surgical Management of Unstable Angina Pectoris
Clin. Cardiol. 2. 311-316 (I979) G. Witzstrock Publishing House. Inc. Editorial Initial Medical and Surgical Management of Unstable Angina Pectoris Introduction The purpose of this report is to review
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationBEDSIDE ASSESSMENT OF PATIENTS WITH STEMI
BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI Prof. Maria Dorobantu, PhD, FESC, FACC Emergency Hospital of Bucharest, Romania Presenter Disclosures There are no conflicts/ grants/ disclosures for this presentation.
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationCardiac Remodeling.
Cardiac Remodeling Peter S. Rahko, M.D. Associate Professor of Medicine University of Wisconsin School of Medicine and Public Health Cardiovascular Medicine Division, Department of Medicine, Madison, WI
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01158-X Dilated
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationDiabetes and Heart Failure
Diabetes and Heart Failure A common and fatal combination A Aspects on epidemiology, prognosis diagnosis and therapy Lars Rydén Department of Medicine Karolinska Institutet Stockholm, Sweden Diabetes and
More informationThe Value of Stress MRI in Evaluation of Myocardial Ischemia
The Value of Stress MRI in Evaluation of Myocardial Ischemia Dr. Saeed Al Sayari, MBBS, EBCR, MBA Department of Radiology and Nuclear Medicine Mafraq Hospital, Abu Dhabi United Arab Emirates Introduction
More information